ALDH1A1 Maintains Ovarian Cancer Stem Cell-Like Properties by Altered Regulation of Cell Cycle Checkpoint and DNA Repair Network Signaling

Objective Aldehyde dehydrogenase (ALDH) expressing cells have been characterized as possessing stem cell-like properties. We evaluated ALDH+ ovarian cancer stem cell-like properties and their role in platinum resistance. Methods Isogenic ovarian cancer cell lines for platinum sensitivity (A2780) and platinum resistant (A2780/CP70) as well as ascites from ovarian cancer patients were analyzed for ALDH+ by flow cytometry to determine its association to platinum resistance, recurrence and survival. A stable shRNA knockdown model for ALDH1A1 was utilized to determine its effect on cancer stem cell-like properties, cell cycle checkpoints, and DNA repair mediators. Results ALDH status directly correlated to platinum resistance in primary ovarian cancer samples obtained from ascites. Patients with ALDHHIGH displayed significantly lower progression free survival than the patients with ALDHLOW cells (9 vs. 3 months, respectively p<0.01). ALDH1A1-knockdown significantly attenuated clonogenic potential, PARP-1 protein levels, and reversed inherent platinum resistance. ALDH1A1-knockdown resulted in dramatic decrease of KLF4 and p21 protein levels thereby leading to S and G2 phase accumulation of cells. Increases in S and G2 cells demonstrated increased expression of replication stress associated Fanconi Anemia DNA repair proteins (FANCD2, FANCJ) and replication checkpoint (pS317 Chk1) were affected. ALDH1A1-knockdown induced DNA damage, evidenced by robust induction of γ-H2AX and BAX mediated apoptosis, with significant increases in BRCA1 expression, suggesting ALDH1A1-dependent regulation of cell cycle checkpoints and DNA repair networks in ovarian cancer stem-like cells. Conclusion This data suggests that ovarian cancer cells expressing ALDH1A1 may maintain platinum resistance by altered regulation of cell cycle checkpoint and DNA repair network signaling.

[1]  J. Nör,et al.  Endothelial cell-secreted EGF induces epithelial to mesenchymal transition and endows head and neck cancer cells with stem-like phenotype. , 2014, Cancer research.

[2]  P. Jeggo,et al.  DNA DSB repair pathway choice: an orchestrated handover mechanism. , 2014, The British journal of radiology.

[3]  Liewei Wang,et al.  Snail Contributes to the Maintenance of Stem Cell-Like Phenotype Cells in Human Pancreatic Cancer , 2014, PloS one.

[4]  Y. Li,et al.  Isolation and Characterization of Cancer Stem Cells from High-Grade Serous Ovarian Carcinomas , 2014, Cellular Physiology and Biochemistry.

[5]  Dong Wang,et al.  Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts , 2013, Stem cell reports.

[6]  Z. Liang,et al.  Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer , 2013, Oncogene.

[7]  T. Das,et al.  Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells , 2013, British Journal of Cancer.

[8]  Gangduo Wang,et al.  β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK , 2013, International journal of oncology.

[9]  M. Asadi-lari,et al.  Application of stem cells in targeted therapy of breast cancer: a systematic review. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[10]  E. Reed,et al.  CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival , 2012, Clinical & Experimental Metastasis.

[11]  Liang Peng,et al.  Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance , 2012, Cancer Chemotherapy and Pharmacology.

[12]  Ronald D. Alvarez,et al.  Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer , 2011, Clinical Cancer Research.

[13]  K. Griffith,et al.  Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. , 2011, Cancer research.

[14]  A. Allan,et al.  The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem Cells , 2011, Stem Cell Reviews and Reports.

[15]  Kazuhiro Takahashi,et al.  The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary , 2011, Clinical Cancer Research.

[16]  C. Vaziri,et al.  Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition , 2011, Cell cycle.

[17]  M. Matin,et al.  Cancer stem cells and cancer therapy , 2011, Tumor Biology.

[18]  Fang Yu,et al.  Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion , 2010, Oncogene.

[19]  M. Todaro,et al.  Tumorigenic and metastatic activity of human thyroid cancer stem cells. , 2010, Cancer research.

[20]  R. Bast,et al.  Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer , 2010, Molecular Cancer Therapeutics.

[21]  M. Wicha,et al.  Single‐marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase , 2010, Head & neck.

[22]  D. Ma,et al.  Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line , 2010, Cellular and Molecular Life Sciences.

[23]  Jeremy M. Stark,et al.  53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks , 2010, Cell.

[24]  F. Bertucci,et al.  Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[25]  Zhenqiu Liu,et al.  ALDH1A1 Is a Marker for Malignant Prostate Stem Cells and Predictor of Prostate Cancer Patients’ Outcome , 2009, Laboratory Investigation.

[26]  D. Roberts,et al.  CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer , 2009, Stem cells.

[27]  Q. Zhan,et al.  Role for Kruppel-like factor 4 in determining the outcome of p53 response to DNA damage. , 2009, Cancer research.

[28]  Yuliang Wu,et al.  FANCJ helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress. , 2009, Current molecular medicine.

[29]  Feng Jiang,et al.  Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer , 2009, Molecular Cancer Research.

[30]  Si-young Song,et al.  GM-CSF and IL-4 synergistically trigger dendritic cells to acquire retinoic acid-producing capacity , 2009, International immunology.

[31]  R. Chen,et al.  Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance , 2009, Cell cycle.

[32]  Curt Balch,et al.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.

[33]  S. Merajver,et al.  BRCA1 regulates human mammary stem/progenitor cell fate , 2008, Proceedings of the National Academy of Sciences.

[34]  K. Kaestner,et al.  Krüppel-like factor 4 exhibits antiapoptotic activity following γ-radiation-induced DNA damage , 2007, Oncogene.

[35]  P. Cartron,et al.  Mitochondria as the target of the pro-apoptotic protein Bax. , 2006, Biochimica et biophysica acta.

[36]  A. D’Andrea.  The Fanconi Anemia/BRCA Signaling Pathway: Disruption in Cisplatin-Sensitive Ovarian Cancers , 2003, Cell cycle.

[37]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[38]  M. Willingham,et al.  Induction of apoptosis by gemcitabine in BG-1 human ovarian cancer cells compared with induction by staurosporine, paclitaxel and cisplatin , 1998, Apoptosis.

[39]  M. van Glabbeke,et al.  Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[41]  P. O'Connor,et al.  Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines , 1992, Molecular and cellular biology.

[42]  A. Eastman,et al.  Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. , 1991, The Journal of clinical investigation.

[43]  Yu‐Chi Wang,et al.  Tumorigenesis and Neoplastic Progression ALDH 1-Bright Epithelial Ovarian Cancer Cells Are Associated with CD 44 Expression , Drug Resistance , and Poor Clinical Outcome , 2012 .

[44]  S. Bapat.  Human ovarian cancer stem cells Focus on Stem Cells in Human Reproduction , 2010 .

[45]  K. Kaestner,et al.  Krüppel-like factor 4 exhibits antiapoptotic activity following gamma-radiation-induced DNA damage. , 2007, Oncogene.

[46]  D. Peeper,et al.  KLF4, p21 and context-dependent opposing forces in cancer , 2006, Nature Reviews Cancer.

[47]  M. Glabbeke,et al.  Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of704 patients , 2005 .